COMPATIBILITY OF PHARMACEUTICAL PRODUCTS AND CONTACT MATERIALS
COMPATIBILITY OF PHARMACEUTICAL PRODUCTS AND CONTACT MATERIALS

Safety Considerations Associated with Extractables and Leachables

DENNIS JENKE
To My Family,
In case you were wondering, this is where all that time went.
CONTENTS

PREFACE AND ACKNOWLEDGMENTS xv

PART A  GENERAL CONCEPTS 1

1.  Introduction 3

   General Discussion, 3
   Key Definitions, 6
      The Interacting Parties, 6
      Extractables versus Leachables, 7
   Regulatory Perspectives for Performing Compatibility and/or
      Safety Assessments, 13
   The U.S. Food and Drug Administration Guidance for
      Industry: Container Closure Systems for Packaging Human
      Drugs and Biologics, 14
   European Medicines Agency (EMEA) Guideline on Plastic
      Immediate Packaging Materials, 15
   FDA Guidance for Industry, Inhalation Products, 18
   Medical Devices, 20
   An Overview of Strategies for Performing Safety
      Assessments, 21
   The Generalized Strategy for Safety Assessments, 22
   Moving Forward, 24
   References, 25
2. **Nomenclature and General Concepts**  
General, 27  
Nomenclature, 27  
  Primary Definitions, 28  
  Constituents of a Material or Construct, 29  
Classification of Extracting Media, 31  
Classification of Extraction Strategies, 32  
Example Extraction Conditions Applied to a Model System, 39  
Correlation, 43  
Factors That Influence the Linking of Extractables and Leachables, 44  
A Hierarchy for Linkages between Extractables and Leachables, 44  
Decisions Concerning the Required Rigor for Linkages, 47  
Circumstances Requiring the Linking of Extractables and Leachables, 48  
Identification and Quantitation, 50  
Risks and Risk Management, 55  
  Risk Categories Related to Biological Assessment of Medical Devices, 58  
  Risk Categories Related to Assessment of Primary Packaging and/or Container–Closure Systems, 58  
The General Dimensions of Risk, 64  
Utilization of Risk Classification Profiles, 68  
Risk Classification in Indirect Contact Situations, 71  
The Construct Itself as a Contributor to Risk, 73  
References, 74

3. **Extractables, Leachables, and the Product Life Cycle**  
General, 77  
Discussion of the Components of the Master Flow Diagram, 78  
Observations, 83  
Application of the Process Map, 87

**PART B  MATERIAL CHARACTERIZATION**  

4. **Material Screening and Characterization**  
Overview, 91  
General Principles, 94
Compendial Compliance, 97
  United States Pharmacopeia, 98
  Japanese Pharmacopeia, 101
  European Pharmacopeia, 102
Compositional Characterization, General Concepts, 103
Compositional Characterization by Collecting Available Material Information, 104
  General, 104
  Collecting Extractables Information from the Material Supplier, 106
Compositional Characterization by Material Testing, Extractables Survey, 112
  Extractables Survey: Extraction, 112
  Case Studies: The Influence of Extraction Medium on the Extractables Survey, 121
  Extractables Survey: Extract Analysis, 124
  Case Study: Extractables Survey for Plastic Tubing Materials, 131
  Case Study: Extractables Survey for an Elastomer Used in OINDP, 136
  Case Study: Extractables Survey for a Rubber Closure Used with Semisolid Drug Products, 137
  Case Study: Extractables Survey for Filter Cartridges Used in Downstream Processing of Pharmaceuticals, 138
Bibliography of Analytical Methods, 139
Reconciliation as a Survey Tool, 140
  Case Study: TOC Reconciliation; Characterization of a Polyolefin Material, 141
Use of Extractables Information in Safety Assessment: Extractables Profile, Total Pool, and Total Available Pool, 142
  Extractions to Establish the Total Pool and Total Available Pool, 143
  Case Study: Total Pool Determination by Successive Extraction, 145
Recap: Components of a Complete Extractables Assessment, 146
Caveats in Using Extractables Information for Safety Assessment, 149
Chemical Characterization: Device Perspective per ISO 10993-18, 152
References, 154
PART C CONSTRUCT QUALIFICATION

5. The Prototype Stage

General Comments, 159
The Simulation Study, 161
  Generating the Simulating Extract, 162
  Simulating the Contact Parameters, 164
  Simulating the Therapeutic Product, 166
  Simulating the Exposure Parameters, 169
Analyzing the Simulating Extract, 171
Case Study: Modeling of the Impact of Solubilizing Agents on Leachables Accumulation, 172
Case Study: Accumulation of Organic Leachables from Plastic Biopharmaceutical Process Containers, 174
Case Study: Accumulation of Label-Related Leachables in a Solid Dosage Form, 179
Case Study: Accumulation of Caprolactam Oligomers Leached from Nylon-6 Material, 180
Application of the Analytical Threshold, 181
The Preliminary Toxicological Assessment, 184
Case Study: Assessment of Cyclohexanone Limits for Containers, 188
Exiting the Prototype Stage, 188
References, 189

6. The Early Development Stage

General Comments, 191
Target Leachables, 192
Method Development, Evaluation, and Validation, 194
  Method Development (Optimization), 195
Prerequisites to Method Optimization, 195
Overview of the Method Optimization Process, 197
Conduct of a Method Optimization Study, 200
Primary Performance Assessment, 201
Troubleshooting Guide, 202
Secondary Performance Assessment, 204
System Suitability, 205
Robustness, 205
Exiting Method Development–Optimization, 206
The Method Evaluation Process, 206
  General, 206
Aspects of the Evaluation and Validation Processes, 207
Contents of the CTD Sections Relevant to Container Closure Systems and Their Safety Assessment, 252
Section 3.2.P.7, Description, 252
Section 3.2.P.2.4, Suitability, 254
Closing Observations, 262
References, 263

9. Launch 265

PART E PRODUCT MAINTENANCE 271

10. Product Maintenance 273

General Discussion, 273
Ongoing Quality Control, 275
  General, 275
  Incoming Raw Materials, 275
  Manufactured In-Process Goods, 278
  Finished Goods (Final Product), 279
  Process of Developing–Implementing QC Extractables Specifications, 281
Change Control, 282
  General, 282
  Change Control Impact Assessment, 285
  Evaluation Recommendation, 295
  Factors to Consider When Contemplating Changes to Registered Products, 296
Case Study: Differential Approach, 297
  Overview, 297
  General Test Strategy, 297
  Experimental, 298
  Results and Discussion, 299
Principles for Judging Toxicological Equivalency, 304
Disaster Management During Product Maintenance, 305
  Atypical Manufacturing During Product Maintenance, 305
  Product Use Field Issues Encountered During Product Maintenance, 309
Changes in Product Registration Requirements During Product Maintenance, 312
Exiting the Product Maintenance Stage, 313
References, 313
11. Retirement 315

12. Focus on Emerging Concepts 319
   Overview, 319
   Plastic Materials used in Manufacturing Applications, 320
      General, 320
      Regulatory Requirements, 321
      Industry Recommendations, 322
      Case Study: Leachables Evaluation for Bulk Drug
         Substance, 326
      Process for Performing Extractables and Leachables
         Assessments for Disposable Materials Used in
         Bioprocessing, 327
         A Matter of Semantics, 328
   Best Demonstrated Practices in Extractables Assessments, 331
   The Broader Context of Suitability for Use, 337
   An Important Practical Consideration, 340
   Future Considerations, 342
   References, 344

Appendix: Materials Used in Pharmaceutical Constructs and
Their Associated Extractables 347
   References, 370

INDEX 371